An extruded, pressed or particulate fish feed is described. Also described is a method for reduction of the content of undesired nutrients in water discharged from a fish farm, and a process for increasing the mechanical strength or shear resistance of faeces from fish in a fish farm.

Provided are methods to destabilize emulsion feedstocks. Benefits of the provided methods include a reducing or eliminating the amount of acid necessary to process the feedstocks, less processing time, cleaner separation of the resulting phases, and increased recovery of valuable products. In the methods, a moderate temperature is applied to the feedstock to create a first mixture. The moderate temperature may be between 120 and 220 degrees Celsius. The first mixture is mixed at the moderate temperature, such as by staged mixing in some embodiments. Moreover, the first mixture is retained at the moderate temperature for up to six hours. The first mixture is separated into an oil phase, convoluted phase, and a water phase. In some embodiments, the moderate temperature may be 125 to 150 degrees Celsius, such as between 125 and 130 degrees Celsius. Moreover, the first mixture may be retained at the moderate temperature for between forty-five minutes and four hours, such as from two to four hours. The separation may occur at the moderate temperature.

The present invention discloses a multiple modular system for the formation of powders, characterized in that it comprises a tower (1) comprising an interchangeable head A selected from the group consisting of a disk spray unit A1; a nozzle spray unit A2; a dual fluid spray unit A3 and a high temperature spray unit A4; and wherein said tower (1) comprises an interchangeable collector installed in the lower part B of the tower selected from the group consisting of collector type 1 (B1), collector type 2 (B2), collector type 3 (B3) and collector type 4 (B4) or combinations of the same.

The present patent application relates to liquid concentrated vitamin E (and/or vitamin E derivatives) compositions. The liquid composition comprises vitamin E (and/or vitamin E derivatives) and at least 40 wt-% of at least one polyoxyethylene sorbitan monofatty acid ester and said liquid composition has an IU value of at least 0.30 IU/mg (based on the total weight of the liquid composition). Furthermore the present invention is related to the use of such compositions in liquid formulations (especially beverages, such as soft drinks), which are transparent (even after pasteurization).

The present patent application relates to liquid concentrated vitamin E (and/or vitamin E derivatives) compositions. The liquid composition comprises vitamin E (and/or vitamin E derivatives) and at least 40 wt-% of at least one polyoxyethylene sorbitan monofatty acid ester and said liquid composition has an IU value of at least 0.30 IU/mg (based on the total weight of the liquid composition). Furthermore the present invention is related to the use of such compositions in liquid formulations (especially beverages, such as soft drinks), which are transparent (even after pasteurization).

The present invention relates to a method of improving flock uniformity and/or meat quality of a monogastric animal comprising administering to the animal a composition, an animal feed or an animal feed additive comprising one or more microbial muramidases.

The present invention relates to a method of improving flock uniformity and/or meat quality of a monogastric animal comprising administering to the animal a composition, an animal feed or an animal feed additive comprising one or more microbial muramidases.

The present invention relates to novel Raf-1 kinase inhibitor compounds for improving skeletal muscle regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery.

The present invention relates to novel Raf-1 kinase inhibitor compounds for improving skeletal muscle regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery.

The present invention relates to phytase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.